COSCIENS Biopharma Inc. shows modest gains amid recent financial reports.
This week, COSCIENS Biopharma Inc. (CSCI.TO) saw its stock price rise by 2.84% in one day and 2.11% over the past week. This reflects a positive trend, even with a challenging month and year-to-date performance. Investors are closely monitoring the company's financial health and market position, while recent headlines provide context for these stock movements.
Advertisement
COSCIENS Biopharma Inc.
CSCI.TO
CSCI.TO
COSCIENS Biopharma Inc.
WealthAwesomeAdvertisement
Market cap
$7.48M
52W high
$14.80
52W low
$1.10
1W change
+2.11%
Beta
1.89
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CSCI's historical volatility
30-Day Vol
573.8%
Annualized
90-Day Vol
351.2%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$8.67
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$7.69 | C$1.06 – C$55.73 |
| 60 trading days | C$8.17 | C$0.50 – C$134.30 |
| 90 trading days | C$8.67 | C$0.28 – C$267.45 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Although COSCIENS Biopharma Inc. has achieved significant year-to-date gains, recent financial results and operational challenges suggest that investors should remain cautious about the stock's future performance.
Year-to-date, COSCIENS Biopharma Inc. stock has surged by 150.00%.
The stock's impressive year-to-date performance sharply contrasts with its recent monthly decline of 10.49%, highlighting volatility in its price action.
Bull case
The company reported a net income of $10.8 million for Q1 2026, indicating potential profitability and operational strength. This could attract more investors looking for solid opportunities in the market.
Bear case
Despite recent gains, COSCIENS faces challenges, including a Management Cease Trade Order and a notable decline in its moving averages. These factors suggest instability and potential risks for shareholders.
Recent Price Action
Advertisement
COSCIENS Biopharma Inc. closed at C$7.62 on the last trading day, marking a daily gain of 2.84% and a weekly increase of 2.11%. However, the stock has experienced a decline of 10.49% over the past month, indicating some volatility in its trading performance.
Company News and Headlines
Recent headlines surrounding COSCIENS Biopharma include the report of a net income of $10.8 million for Q1 2026, primarily from discontinued operations. Additionally, the company has encountered challenges with a Management Cease Trade Order issued by the Ontario Securities Commission due to a potential delay in filing annual financial statements. This mix of positive financial reporting and regulatory hurdles presents a complex picture for investors.
Technical Picture
The technical indicators for COSCIENS Biopharma reveal significant challenges. The stock is currently trading well below its 50-day moving average of C$17.40 and its 200-day moving average of C$22.63, indicating a bearish trend. The 52-week range is between C$1.10 and C$14.80, with the current price at approximately 48% of this range. The stock has a beta of 1.89, suggesting higher volatility compared to the market, and the current trading volume of 900 shares is below the 20-day average volume of 1,455 shares, indicating reduced trading activity.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
